~~<i id='DB3BA43BFD'><strike id='DB3BA43BFD'><tt id='DB3BA43BFD'><pre id='DB3BA43BFD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：entertainment 2025-09-02 22:07:12 - browse：56

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Dewpoint Therapeutics lays off staff after losing partnerships

hotspot

focus

leisure time

hotspot

focus

hotspot

Illustration:STAT;ScreencaptureOncethedomainofagingTVstars,hawkinghealthproductsfromvitaminstodiabet

WSS

FDA clears AI tool for detecting skin cancer

Key Senate panel to consider PBM, drug pricing reform package

Key Senate panel to consider PBM, drug pricing reform package

Readout Newsletter: Merck, J&J, and long Covid

Parkinson’s finding may lead to tests and, someday, treatments

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

focus

Wikipedia

hotspot

Supreme Court strikes down use of affirmative action

Explaining an after

Sports medicine is finally prioritizing gender equality

The surgeon had a dilemma only a Nazi medical text could resolve

Heart attack and stroke risk calculators need revising

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Anesthesiologist group: stop taking Ozempic before surgery

My yearlong odyssey to get my son’s ADHD medication covered

focus

Kidney transplant patients stopped immunosuppressants in trial

Independent physicians launch a new lobbying group

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Coloradans with cystic fibrosis could lose access to Trikafta

All of Us, NIH's precision medicine initiative, gets a big boost

leisure time

hotspot

focus

hotspot